

Clinical Policy: Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

Reference Number: CP.MP.209

Date of Last Revision: 06/21

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Multiplex molecular panels allow for the qualitative detection of nucleic acid from multiple viral, parasitic, and bacterial pathogens in stool samples from those with symptoms of gastroenteritis or infectious colitis. The Food and Drug Administration (FDA) have cleared several panels for diagnosis of gastrointestinal infections. This policy addresses the medical necessity criteria for Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing.

Policy/Criteria

- I. It is the policy of health plans affiliated with Centene Corporation[®] that gastrointestinal pathogen panel testing of up to five targets is considered **medically necessary** for either of the following:
 - A. Diarrhea for more than seven days with fever and suspected bacteremia;
 - B. Suspected enteric fever (i.e., typhoid or paratyphoid) in an individual with a history of recent travel to an endemic region (e.g., South and Southeast Asia, Central and South America, Africa, Central and East Asia, and Oceania [Southeast Asia, and southern Africa) or who has consumed foods prepared by people with recent endemic exposure.
- II. It is the policy of health plans affiliated with Centene Corporation that gastrointestinal pathogen panel testing of up to 11 targets is considered **medically necessary** for either of the following:
 - A. Diarrhea for more than seven days with fever and suspected bacteremia, and the individual is at risk for *Clostridium difficile* (*C. difficile*) colitis;
 - B. Persistent diarrhea in immunocompromised individuals.
- III. It is the policy of health plans affiliated with Centene Corporation that gastrointestinal pathogen panel testing of greater than 11 targets is considered **medically necessary** for persons who are critically ill or immunocompromised in a healthcare setting, such as emergency department or inpatient hospital, including those in observation status.

Background

Infectious gastroenteritis is a significant global health concern characterized by diarrhea, vomiting, and other symptoms, and can lead to life-threatening dehydration in severe cases. Causes include infections with bacteria (e.g., *Clostridium difficile*, *Escherichia coli*, *Shigella*), viruses (e.g., norovirus, rotavirus), or parasites (e.g., *Cryptosporidium*, *Giardia*).⁴

Nucleic acid amplification testing (NAAT) uses a microorganism's DNA or RNA to directly identify specific bacteria, viruses, and/or protozoa rather than standard microorganism detection techniques (e.g., bacterial culture, individual real-time PCR, immunoassays, and/or microscopy). Multiplex NAAT tests are included in the larger grouping of culture-independent diagnostic tests

CLINICAL POLICY

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

(CIDT). Multipathogen NAATs can simultaneously detect viral, parasitic, and bacterial agents, including some pathogens that previously could not be easily detected in the clinical setting such as norovirus, and enterotoxigenic *E. coli* (ETEC), enteropathogenic *E. coli* (EPEC), and enteroaggregative *E. coli* (EAEC), in less time than traditional methods.

Multipathogen NAAT is associated with high clinical validity for the majority of available pathogenic targets relative to conventional testing, and has a more rapid turnaround time compared with most types of conventional testing.⁴ Drawbacks of molecular technologies include the need to predefine the particular microbes sought, detection of microbes at non-pathogenic levels, and increased detection of mixed infections; the relative importance of each pathogen identified may be unclear.¹

CIDT are touted as providing a more comprehensive assessment of disease etiology by increasing the diagnostic yield compared with conventional diagnostic tests, permitting earlier initiation of appropriate therapeutic agents targeted to the detected pathogen(s), if any, rather than empirical therapy until culture results are available. The short time to results could reduce inappropriate use of antimicrobial agents to treat infections that do not require antimicrobial therapy and could shorten the time to targeted management and isolation measures for certain infections (e.g., STEC O157.)²

Individuals who are immunocompromised are more likely to experience severe or prolonged illness. Diarrhea in immunocompromised patients may involve a broad spectrum of potential causes, including bacterial, viral, parasitic, and fungal pathogens depending on underlying immune status.²

Infectious Diseases Society of America

- Culture-independent, including panel-based multiplex molecular diagnostics from stool and blood specimens, and, when indicated, culture-dependent diagnostic testing should be performed when there is a clinical suspicion of enteric fever or diarrhea with bacteremia
- A broad differential diagnosis is recommended in immunocompromised people with diarrhea, especially those with moderate and severe primary or secondary immune deficiencies, for evaluation of stool specimens by culture, viral studies, and examination for parasites (strong, moderate). People with acquired immune deficiency syndrome (AIDS) with persistent diarrhea should undergo additional testing for other organisms including, but not limited to, *Cryptosporidium*, *Cyclospora*, *Cystoisospora*, microsporidia, *Mycobacterium avium* complex, and cytomegalovirus.
- Clinical consideration should be a part of interpreting results of multiple-pathogen nucleic acid amplification tests because these assays are DNA based and detect both viable and nonviable organisms.

American College of Gastroenterology

CLINICAL POLICY

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

- Stool diagnostic studies may be used if available in cases of dysentery, moderate-to-severe disease, and symptoms lasting >7 days to clarify the etiology of the patient’s illness and enable specific directed therapy.
- Traditional methods of diagnosis (bacterial culture, microscopy with and without special stains and immunofluorescence, and antigen testing) fail to reveal the etiology of the majority of cases of acute diarrheal infection. If available, the use of Food and Drug Administration-approved culture-independent methods of diagnosis can be recommended at least as an adjunct to traditional methods.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

Table 1: CPT codes that support medical necessity in any place of service

CPT® Codes	Description
87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets

Table 2: CPT codes that support medical necessity when billed with place of service codes in Table 3

CPT® Codes	Description
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
0097U	Gastrointestinal pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 22 targets (Campylobacter [C. jejuni/C. coli/C. upsaliensis], Clostridium difficile [C. difficile] toxin A/B, Plesiomonas shigelloides, Salmonella, Vibrio [V. parahaemolyticus/V. vulnificus/V. cholerae], including specific identification of Vibrio cholerae, Yersinia enterocolitica, Enterohaggative Escherichia coli [EAEC], Enteropathogenic Escherichia coli [EPEC], Enterotoxigenic

CPT® Codes	Description
	Escherichia coli [ETEC] It/st, Shiga-like toxin-producing Escherichia coli [STEC] stx1/stx2 [including specific identification of the E. coli O157 serogroup within STEC], Shigella/Enteroinvasive Escherichia coli [EIEC], Cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia [also known as G. intestinalis and G. duodenalis], adenovirus F 40/41, astrovirus, norovirus GI/GII, rotavirus A, sapovirus [Genogroups I, II, IV, and V])

Table 3: Place of service codes supporting medical necessity for codes in Table 2

Place of Service Code	Place of Service Name	Place of Service Description
21	Inpatient Hospital	A facility other than psychiatric which primarily provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services by, or under, the supervision of physicians to patients admitted for a variety of medical conditions.
22*	Outpatient Hospital (Observation)	A portion of a hospital which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization.
23	Emergency Room – Hospital	A portion of a hospital where emergency diagnosis and treatment of illness or injury is provided.

** NOTE: PCR testing in an outpatient place of service is reimbursable only when performed as part of the diagnostic work-up for a patient admitted for Observation.*

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed.	02/21	
References reviewed and updated.	06/21	06/21

References

- Riddle MS, Dupont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults Am J Gastroenterol. 2016 May;111(5):602-22. doi: 10.1038/ajg.2016.126.
- Shane AL, Mody RK, Crump JA, Tarr PI, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):e45-e80. doi: 10.1093/cid/cix669.
- Binnicker MJ. Multiplex Molecular Panels for Diagnosis of Gastrointestinal Infection: Performance, Result Interpretation, and Cost-Effectiveness. J Clin Microbiol. 2015 Dec;53(12):3723-8. doi: 10.1128/JCM.02103-15.

CLINICAL POLICY

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

4. Noridian Local Coverage Determination. L373350. Foodborne Gastrointestinal panels identified by Multiplex Nucleic Acid Amplification. Effective Feb. 11, 2019. Accessed June 14, 2021.
5. Hayes Molecular Test Assessment. Multiplex Molecular Panels for Diagnosis of Gastrointestinal Infection. Dec 18, 2018. Annual Review: Jan 14, 2020. Accessed May 21, 2021.
6. Beal HG, Tremblay EE, Toffel S, et al. A Gastrointestinal PCR Panel Improves Clinical Management and Lowers Health Care Costs. *J Clin Microbiol.* 2017 Dec 26;56(1):e01457-17. doi: 10.1128/JCM.01457-17.
7. Torres-Miranda D, Akselrod H, Karsner R, et al. Use of BioFire FilmArray gastrointestinal PCR panel associated with reductions in antibiotic use, time to optimal antibiotics, and length of stay. *BMC Gastroenterol* 2020 Jul 29;20(1):246. doi: 10.1186/s12876-020-01394-w.
8. Sobczyk J, Jain S, Sun X, et al. Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Patients With HIV Infection. *Open Forum Infect Dis.* 2020 Jan 6;7(1):ofz547. doi: 10.1093/ofid/ofz547. eCollection 2020 Jan
9. Cybulski RJ, Bateman AC, Bourassa L, et al. Clinical Impact of a Multiplex Gastrointestinal Polymerase Chain Reaction Panel in Patients with Acute Gastroenteritis. *Clin Infect Dis* 2018 Nov 13;67(11):1688-1696. doi: 10.1093/cid/ciy357.
10. Axelrad JE, Freedberg DE, Whittier S, et al. Impact of Gastrointestinal Panel Implementation on Health Care Utilization and Outcomes. *J Clin Microbiol* 2019 Feb 27;57(3):e01775-18. doi: 10.1128/JCM.01775-18.
11. LaRocque R, Harris JB. Approach to the adult with acute diarrhea in resource-rich settings. In: UpToDate. Calderwood SB (Ed) UpToDate. June 26, 2020. Accessed May 21, 2021.
12. Novitas Solutions, Inc Local Coverage Article A56642. Billing and Coding: Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs). Effective December 30, 2019. Accessed June 14, 2021.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,

CLINICAL POLICY

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid members/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or

CLINICAL POLICY

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.